person · Reporting owner

Franchini Indrani Lall

Disclosed activity across 3 companies

Tapewire entity: 28190
SEC CIK: 0001708764

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	EVP, CLO & Secretary	February 27, 2024	February 29, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date February 27, 2024 · Filed February 29, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,133	Ending reported balance After 2024-02-28 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2024-02-27 · Exercise / conversion · Acquired 878 · Balance 4,462 Row 2 · 2024-02-28 · Sale · Disposed 142 · Balance 4,320 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2024-02-28 · Sale · Disposed 111 · Balance 4,209 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2024-02-28 · Sale · Disposed 66 · Balance 4,143 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2024-02-28 · Sale · Disposed 9 · Balance 4,134 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2024-02-28 · Sale · Disposed 1 · Balance 4,133 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-27	Direct	1,754	Reported balance After 2024-02-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-27 · Exercise / conversion · Disposed 878 · Balance 1,754 F6: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F7: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F8: On February 27, 2023, the reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F7: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.

F8: On February 27, 2023, the reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALEXION PHARMACEUTICALS, INC.

Report date July 21, 2021 · Filed July 23, 2021

Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2021-07-21 transaction · row 1 1 source row Row 1 · 2021-07-21 · Disposition to issuer · Disposed 116,075 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $100.14 · Expires 2027-06-07	Direct	0	Reported balance After 2021-07-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-21 · Disposition to issuer · Disposed 25,165 · Balance 0 F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").

F2: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.

AVANOS MEDICAL, INC.

Report date July 27, 2026 · Filed July 28, 2026

Section 16 reporting ended · disclosed 2026-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2026-07-27 transaction · row 1 1 source row Row 1 · 2026-07-27 · Disposition to issuer · Disposed 4,817 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-07-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-27 · Disposition to issuer · Disposed 12,003 · Balance 0 F2: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F3: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.

F2: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.

F3: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 27, 2026 Filed Jul 28, 2026 21:37 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerRestricted Share Units · Derivative	12,003	$25.00	$300,075.00	Disclosure SEC source: 0001606498-26-000107 · wk-form4_1785274622.xml · derivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,003 shares Expires not disclosed F2 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F3 · price: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). Read SEC document
July 27, 2026 Filed Jul 28, 2026 21:37 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerCommon Stock	4,817	$25.00	$120,425.00	Disclosure SEC source: 0001606498-26-000107 · wk-form4_1785274622.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. Read SEC document
May 08, 2026 Filed May 12, 2026 15:40 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantRestricted Share Units · Derivative	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-26-000075 · wk-form4_1778600427.xml · derivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,003 Underlying: Common Stock · 12,003 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025. F2 · derivative.exercise_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. Read SEC document
January 02, 2025 Filed Jan 6, 2025 18:49 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-25-000012 · wk-form4_1736189392.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,820 F1 · shares: Represents restricted share units issued to the Reporting Person on January 2, 2025 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1	$158.09	$158.09	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 6 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,133 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	9	$157.30	$1,415.70	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 5 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,134 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	66	$156.38	$10,321.08	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 4 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,143 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	111	$155.45	$17,254.95	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 3 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,209 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 28, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	142	$154.54	$21,944.68	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,320 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 27, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionRestricted Stock Units · Derivative	878	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · derivative · entry 7 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,754 Underlying: Common Stock · 878 shares Expires 2026-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F7 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F8 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. Read SEC document
February 27, 2024 Filed Feb 29, 2024 21:16 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	878	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000016 · edgardoc.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 02, 2024 Filed Feb 5, 2024 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	269	$172.38	$46,370.22	Disclosure SEC source: 0001735276-24-000002 · edgardoc.xml · nonDerivative · entry 4 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,584 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $171.80 to $172.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 02, 2024 Filed Feb 5, 2024 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	820	$171.14	$140,334.80	Disclosure SEC source: 0001735276-24-000002 · edgardoc.xml · nonDerivative · entry 3 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,853 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $170.58 to $171.54. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 02, 2024 Filed Feb 5, 2024 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	502	$170.01	$85,345.02	Disclosure SEC source: 0001735276-24-000002 · edgardoc.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,673 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $169.57 to $170.57. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionRestricted Stock Units · Derivative	5,175	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000002 · edgardoc.xml · derivative · entry 5 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,175 Underlying: Common Stock · 5,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F6 · derivative.exercise_date: On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2024, the second tranche of restricted stock units from the February 1, 2022 grant vested and was released, as reported on this Form 4. F6 · derivative.expiration_date: On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2024, the second tranche of restricted stock units from the February 1, 2022 grant vested and was released, as reported on this Form 4. Read SEC document
February 01, 2024 Filed Feb 5, 2024 21:05 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	5,175	$0.00	$0.00	Disclosure SEC source: 0001735276-24-000002 · edgardoc.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 06, 2023 Filed Apr 10, 2023 20:29 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	3,500	$210.00	$735,000.00	Disclosure SEC source: 0001735276-23-000038 · edgardoc.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022. Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:21 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	5,449	$0.00 Strike: $190.01	$0.00	Disclosure SEC source: 0001735276-23-000026 · edgardoc.xml · derivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,449 Underlying: Common Stock · 5,449 shares Expires 2033-02-27 F4 · shares: Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date. Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:21 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantRestricted Stock Units · Derivative	2,632	$0.00	$0.00	Disclosure SEC source: 0001735276-23-000026 · edgardoc.xml · derivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,632 Underlying: Common Stock · 2,632 shares Expires 2026-02-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · shares: Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 5,263 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest. F3 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	5	$227.38	$1,136.90	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · nonDerivative · entry 5 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	586	$226.62	$132,799.32	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · nonDerivative · entry 4 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,505 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	1,007	$225.80	$227,380.60	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · nonDerivative · entry 3 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,091 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 02, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	SaleCommon Stock	77	$223.97	$17,245.69	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,098 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionRestricted Stock Units · Derivative	5,175	$0.00	$0.00	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · derivative · entry 6 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,350 Underlying: Common Stock · 5,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F6 · derivative.exercise_date: On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2023 the first third vested and released as reported on this Form 4. F6 · derivative.expiration_date: On February 1, 2022 the reporting person received 15,525 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 1, 2023 the first third vested and released as reported on this Form 4. Read SEC document
February 01, 2023 Filed Feb 3, 2023 22:46 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	Exercise / conversionCommon Stock	5,175	$0.00	$0.00	Disclosure SEC source: 0001735276-23-000007 · edgardoc.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 01, 2022 Filed Feb 10, 2022 01:59 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantStock Option (right to buy) · Derivative	29,182	$0.00 Strike: $144.93	$0.00	Disclosure SEC source: 0001735276-22-000012 · edgardoc.xml · derivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,182 Underlying: Common Stock · 29,182 shares Expires 2032-01-31 F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document
February 01, 2022 Filed Feb 10, 2022 01:59 UTC	ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132	GrantRestricted Stock Units · Derivative	15,525	$0.00	$0.00	Disclosure SEC source: 0001735276-22-000012 · edgardoc.xml · derivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, CLO & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,525 Underlying: Common Stock · 15,525 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: The restricted stock units vest ratably on each of the first, second and third anniversaries of the Grant Date. F2 · derivative.expiration_date: The restricted stock units vest ratably on each of the first, second and third anniversaries of the Grant Date. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:37 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerOption to Purchase Common Stock · Derivative	25,165	$100.14 Strike: $100.14	$2,520,023.10	Disclosure SEC source: 0000899866-21-000066 · wf-form4_162707265918164.xml · derivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 25,165 shares Expires 2027-06-07 F2 · derivative.exercise_date: Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration. Read SEC document
July 21, 2021 Filed Jul 23, 2021 16:37 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Disposition to issuerCommon Stock, par value $.0001 per share	116,075	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000066 · wf-form4_162707265918164.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Read SEC document
July 14, 2021 Filed Jul 16, 2021 16:53 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	25,813	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000056 · wf-form4_162646878098060.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,075 F2 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2020 under the 2017 Stock Incentive Plan. Read SEC document
July 14, 2021 Filed Jul 16, 2021 16:53 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	26,812	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000056 · wf-form4_162646878098060.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,262 F1 · shares: On July 14, 2021 the Leadership and Compensation Committee certified that certain performance metrics under previously granted performance stock units were satisfied. These performance stock units were previously granted in February 2019 under the 2017 Stock Incentive Plan. Read SEC document
June 08, 2021 Filed Jun 9, 2021 16:50 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	928	$177.00	$164,256.00	Disclosure SEC source: 0000899866-21-000048 · wf-form4_162327180875734.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,450 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
February 28, 2021 Filed Mar 2, 2021 17:54 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	18,033	$0.00	$0.00	Disclosure SEC source: 0000899866-21-000025 · wf-form4_161472565376598.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,378 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:08 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	2,913	$157.96	$460,137.48	Disclosure SEC source: 0000899866-20-000094 · wf-form4_160832927928084.xml · nonDerivative · entry 3 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,345 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:08 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	16,925	$157.96	$2,673,473.00	Disclosure SEC source: 0000899866-20-000094 · wf-form4_160832927928084.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,258 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. Read SEC document
December 16, 2020 Filed Dec 18, 2020 17:08 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	37,965	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000094 · wf-form4_160832927928084.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,183 F1 · shares: Shares acquired on vesting of Performance Stock Units previously granted on February 28, 2018 under the 2017 Stock Incentive Plan. Read SEC document
June 08, 2020 Filed Jun 9, 2020 17:05 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	1,433	$115.00	$164,795.00	Disclosure SEC source: 0000899866-20-000065 · wf-form4_159173671433425.xml · nonDerivative · entry 3 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,218 F2 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document
June 08, 2020 Filed Jun 9, 2020 17:05 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	5,420	$114.61	$621,186.20	Disclosure SEC source: 0000899866-20-000065 · wf-form4_159173671433425.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,651 F2 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document
June 08, 2020 Filed Jun 9, 2020 17:05 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,403	$114.61	$160,797.83	Disclosure SEC source: 0000899866-20-000065 · wf-form4_159173671433425.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,071 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
March 02, 2020 Filed Mar 3, 2020 18:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,267	$90.54	$114,714.18	Disclosure SEC source: 0000899866-20-000018 · wf-form4_158327740132826.xml · nonDerivative · entry 2 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,474 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2020 Filed Mar 3, 2020 18:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	9,520	$0.00	$0.00	Disclosure SEC source: 0000899866-20-000018 · wf-form4_158327740132826.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,741 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 07, 2020 Filed Feb 10, 2020 16:57 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,406	$102.97	$144,775.82	Disclosure SEC source: 0000899866-20-000014 · wf-form4_158137184419381.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,221 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $102.97 - $103.24. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
July 01, 2019 Filed Jul 2, 2019 16:41 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	4,500	$132.78	$597,510.00	Disclosure SEC source: 0000899866-19-000079 · wf-form4_156210004597380.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,627 F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. Read SEC document
June 07, 2019 Filed Jun 11, 2019 18:35 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,404	$118.61	$166,528.44	Disclosure SEC source: 0000899866-19-000074 · wf-form4_156029251991291.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,127 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
February 28, 2019 Filed Mar 4, 2019 17:35 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	625	$132.93	$83,081.25	Disclosure SEC source: 0000899866-19-000036 · wf-form4_155173889807803.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,281 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $135.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2019 Filed Mar 5, 2019 20:21 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	8,250	$0.00	$0.00	Disclosure SEC source: 0000899866-19-000050 · wf-form4_155183526477412.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,531 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 07, 2019 Filed Feb 11, 2019 18:18 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	Tax withholdingCommon Stock, par value $.0001 per share	1,398	$119.57	$167,158.86	Disclosure SEC source: 0000899866-19-000011 · wf-form4_154992711355552.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,906 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $119.43 - $119.57. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
November 28, 2018 Filed Nov 30, 2018 18:15 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	2,605	$118.13	$307,728.65	Disclosure SEC source: 0000899866-18-000135 · wf-form4_154361972463867.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,304 Read SEC document
June 08, 2018 Filed Jun 12, 2018 16:52 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	1,466	$118.53	$173,764.98	Disclosure SEC source: 0000899866-18-000104 · wf-form4_152883671232830.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,909 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
February 28, 2018 Filed Mar 2, 2018 17:01 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	8,344	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000060 · wf-form4_152002804041916.xml · nonDerivative · entry 1 Franchini Indrani Lall · CIK 0001708764 · EVP, Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,375 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.